Can anthropometric indices predict the chance of hypertension? A multicentre cross-sectional study in Iran.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
23 11 2022
Historique:
entrez: 23 11 2022
pubmed: 24 11 2022
medline: 26 11 2022
Statut: epublish

Résumé

This study aims to assess the prevalence of hypertension (HTN), and determine the relationship between HTN and anthropometric indices including fat distribution, body mass index (BMI), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) in Shiraz Heart Study. In this cross-sectional study, subjects were enrolled in 25 clinics in Shiraz. I.R. Iran between 2019 and 2021. A total number of 7225 individuals were selected, aged between 40 and 70 years of whom 52.3% were female. Among the people living in Shiraz, individuals living far from clinics, cases of mental or physical disabilitiy and documented cardiovascular diseases were excluded. Primary outcome: The association of body composition, WHR, WHtR and BMI with HTN. The sensitivity and specificity of the WHtR for the prediction of HTN. HTN prevalence was 19.3%. Obesity prevalence was estimated to be 28.5%. WHR and lean body mass showed a significant association with HTN (p<0.05). Receiver operating characteristic for WHtR yielded an area under the curve of 0.62 (95% CI 0.61 to 0.64) and 0.63 (95% CI 0.62 to 0.65) for males and females, respectively. The optimal threshold value yielded 0.54 in men and 0.61 in women. The sensitivity was 72.3% and 73.9% in women and men, with specificity of 48.4% and 44.3%, respectively. HTN had a meaningful association with all the noted anthropometric indices. WHtR performed well as a predictor of HTN.

Identifiants

pubmed: 36418117
pii: bmjopen-2022-062328
doi: 10.1136/bmjopen-2022-062328
pmc: PMC9685002
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e062328

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
J Am Soc Hypertens. 2016 Oct;10(10):753-754
pubmed: 27660007
Indian J Physiol Pharmacol. 2014 Jan-Mar;58(1):39-44
pubmed: 25464675
BMC Cardiovasc Disord. 2020 Dec 1;20(1):503
pubmed: 33256609
Lancet Glob Health. 2018 Jul;6(7):e736-e743
pubmed: 29778399
BMC Public Health. 2019 Oct 29;19(1):1416
pubmed: 31664979
Br J Nutr. 2008 May;99(5):931-40
pubmed: 17977473
BMJ Open. 2016 Mar 14;6(3):e010159
pubmed: 26975935
BMC Geriatr. 2019 Dec 23;19(1):371
pubmed: 31870324
Curr Opin Cardiol. 2019 Jul;34(4):342-349
pubmed: 31170095
Medicine (Baltimore). 2018 Nov;97(48):e13262
pubmed: 30508913
Obes Rev. 2012 Mar;13(3):275-86
pubmed: 22106927
J Hypertens. 2018 Nov;36(11):2168-2176
pubmed: 29939946
Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Heliyon. 2020 Jul 17;6(7):e04432
pubmed: 32715126
BMJ Open. 2019 Apr 3;9(4):e026317
pubmed: 30948600
J Hum Hypertens. 2021 Mar;35(3):257-264
pubmed: 32203076
J Am Soc Hypertens. 2018 Aug;12(8):579.e1-579.e73
pubmed: 30219548
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):201-205
pubmed: 30641697
Hypertension. 2020 Aug;76(2):333-341
pubmed: 32419505
Health Sci Rep. 2022 Jan 12;5(1):e483
pubmed: 35036580
J Clin Hypertens (Greenwich). 2019 Nov;21(11):1647-1653
pubmed: 31553131
Nat Rev Nephrol. 2020 Apr;16(4):223-237
pubmed: 32024986
Biomed Res Int. 2020 Aug 11;2020:8179795
pubmed: 32851088
Front Endocrinol (Lausanne). 2020 Feb 26;11:42
pubmed: 32174887
Int J Cardiol Hypertens. 2020 Jul 31;6:100044
pubmed: 33447770
J Hum Hypertens. 1996 Jun;10(6):365-8
pubmed: 8872798
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Acta Med Iran. 2015 Oct;53(10):596-607
pubmed: 26615371
Curr Hypertens Rep. 2019 Apr 4;21(4):27
pubmed: 30949774
Int J Environ Res Public Health. 2020 Jun 19;17(12):
pubmed: 32575484
East Mediterr Health J. 2020 Mar 24;26(3):304-314
pubmed: 32281640
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Int J Cardiol Hypertens. 2020 Nov 03;7:100066
pubmed: 33447787
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
J Hypertens. 2009 Jul;27(7):1472-7
pubmed: 19474763
Cardiovasc Ultrasound. 2020 Aug 13;18(1):33
pubmed: 32791984

Auteurs

Ali Akbari-Khezrabadi (A)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Mohammad Javad Zibaeenezhad (MJ)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Ehsan Shojaeefard (E)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Arzhang Naseri (A)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Shahrokh Mousavi (S)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Shirin Sarejloo (S)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Mohammadreza Karimi (M)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Morteza Hosseinpour (M)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Maryam Salimi (M)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Mehdi Bazrafshan (M)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Amirhossein Salimi (A)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Nader Parsa (N)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Mehrab Sayadi (M)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Iman Razeghian-Jahromi (I)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Fatemeh Zibaeenejad (F)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Seyyed Saeed Mohammadi (SS)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of).

Hamed Bazrafshan Drissi (H)

Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (the Islamic Republic of) hamedbazrafshan@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH